Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer

Thomas, George V, Tran, Chris, Mellinghoff, Ingo K, Welsbie, Derek S, Chan, Emily, Fueger, Barbara, Czernin, Johannes, Sawyers, Charles L·2006·Nature Medicine
DOI 10.1038/nm1337

Cited by (605)

Items 401–500 of 605

  1. Molecular Pathways and Druggable Targets in Head and Neck Squamous Cell Carcinoma
    Farzaneh Kordbacheh, Camile Selim Farah · 2021 · Cancers
  2. Systemtherapie des metastasierten Nierenzellkarzinoms
    Mark Ringhoffer, Ludwig J. Rinnab, R. Küfer, Jochen Greiner · 2009 · Der Urologe
  3. Activation of the Tor/Myc signaling axis in intestinal stem and progenitor cells affects longevity, stress resistance and metabolism in drosophila
    Olha M. Strilbytska, Uliana V. Semaniuk, Kenneth B. Storey, Bruce A. Edgar, Oleh V. Lushchak · 2016 · Comparative Biochemistry and Physiology Part B Biochemistry and Molecular Biology
  4. TRIM7 suppresses cell invasion and migration through inhibiting HIF‐1α accumulation in clear cell renal cell carcinoma
    Chao Yuan, Jun‐Li Liu, Ling Liu, Hongying Jia, Qi Gao, Xiaoyan Wang, Jingjie Zhao · 2021 · Cell Biology International
  5. Expression of 3-Methylcrotonyl-CoA Carboxylase in Brain Tumors and Capability to Catabolize Leucine by Human Neural Cancer Cells
    Eduard Gondáš, Alzbeta Kralova Trancikova, Eva Baranovičová, Jakub Šofránko, Jozef Hatok, Bhavani S. Kowtharapu, Tomáš Galanda, Dušan Dobrota, Peter Kubatka, Dietrich Büsselberg et al. · 2022 · Cancers
  6. Everolimus Personalized Therapy: Second Consensus Report by the International Association of Therapeutic Drug Monitoring and Clinical Toxicology
    Satohiro Masuda, Florian Lemaitre, Markus Johannes Barten, Stein Bergan, Maria Shipkova, Teun van Gelder, Sander Vinks, Eberhard Wieland, Kirsten Bornemann-Kolatzki, Mercè Brunet et al. · 2024 · Therapeutic Drug Monitoring
  7. Everolimus for the treatment of advanced renal cell carcinoma
    Robert John Amato · 2011 · Expert Opinion on Pharmacotherapy
  8. Bisphosphonates and vascular endothelial growth factor-targeted drugs in the treatment of patients with renal cell carcinoma metastatic to bone
    Eduard Vrdoljak, Brian I. Rini, Manuela Schmidinger, Tomislav Omrčen, László Torday, Cezary A. Szczylik, Avishay Sella · 2013 · Anti-Cancer Drugs
  9. A Novel Method for Cancer Subtyping and Risk Prediction Using Consensus Factor Analysis
    Duc Tran, Hung Nguyen, Uyen Q. Le, George N. Bebis, Hung Nguyen Luu, Tin Nguyen · 2020 · Frontiers in Oncology
  10. Synthesis of fluorinated carbazoles via C–H arylation catalyzed by Pd/Cu bimetal system and their antibacterial activities
    Xianqiang Kong, Huizi Zhang, Changsheng Cao, Shengliang Zhou, Guangsheng Pang, Yanhui Shi · 2016 · Bioorganic & Medicinal Chemistry
  11. Identification of p27/KIP1 expression level as a candidate biomarker of response to rapalogs therapy in human cancer
    Guang Chen, Na Yang, Xiang Wang, Si-Yuan Zheng, Yi Chen, Lin-Jiang Tong, Yi-Xue Li, Ling-Hua Meng, Jian Ding · 2010 · Journal of Molecular Medicine
  12. Epidemiology of Renal Cell Carcinoma
    Sujata Narayanan, Priti H. Patel, Alice C. Fan, Sandy Srinivas · 2015 · Springer eBooks
  13. Mechanism of action of rapalogues: the antiangiogenic hypothesis
    Sandrine J. Faivre, Éric Raymond · 2008 · Expert Opinion on Investigational Drugs
  14. Adaptation of Natural Killer Cells to Hypoxia: A Review of the Transcriptional, Translational, and Metabolic Processes
    Teding Chang, Yu-Jie Chen, Jialiu Luo, Cong Zhang, Shun-Yao Chen, Zhi-Qiang Lin, Peidong Zhang, Yunli Shen, Ting-Xuan Tang, Hui Li et al. · 2025 · ImmunoTargets and Therapy
  15. Current status of pharmacotherapy against metastatic renal cell carcinoma in Japan
    Yoshihiro Wada, Wataru Takahashi, Yoshiaki Kawano, Masatoshi Eto · 2012 · International Journal of Urology
  16. Combination therapy in metastatic renal cell carcinoma: Back to the future?
    Luigi Cerbone, Carlo Cattrini, Giacomo Vallome, Maria Maddalena Latocca, Francesco Boccardo, Elisa Zanardi · 2020 · Seminars in Oncology
  17. Inhibition of mtor in Kidney Cancer
    Anil Kapoor · 2009 · Current Oncology
  18. Genitourinary Oncology: Current Status and Future Challenges
    Ronald M. Bukowski · 2011 · Frontiers in Oncology
  19. PLAC1 is an independent predictor of poor survival, and promotes cell proliferation and invasion in cervical cancer
    Rujun Chen, Chan Sheng, Ruyue Ma, Liwen Zhang, Lina Yang, Yaping Chen · 2021 · Molecular Medicine Reports
  20. Inherited disorders as a risk factor and predictor of neurodevelopmental outcome in pediatric cancer
    Nicole J. Ullrich · 2008 · Developmental Disabilities Research Reviews
  21. mTOR/autophagy pathway in the hippocampus of rats suffering intermittent hypoxia preconditioning and global cerebral ischemia-reperfusion
    Yaning Zhao, Xiangfei Guo, Jianmin Li, Chang‐Xiang Chen, Shuxing Li, Cheng-Jing Xu · 2017 · Oncotarget
  22. The Impact of mTOR Inhibitors on the Development of Malignancy
    Edward Kenneth Geissler · 2008 · Transplantation Proceedings
  23. Temsirolimus in metastatic chromophobe renal cell carcinoma after interferon and sorafenib therapy.
    Bernard Paule, Nathalie Brion · 2011 · PubMed
  24. Hypoxia and hypoxia‐inducible factors promote the development of neointimal hyperplasia in arteriovenous fistula
    Nirvana Sadaghianloo, Julie Contenti, Serge Declémy, Damien Ambrosetti, Maša Ždralević, Mounia Tannour‐Louet, Lucilla Fabbri, Gilles Pagès, Frédéric Bost, Réda Hassen‐Khodja et al. · 2021 · The Journal of Physiology
  25. Management of Metastatic Renal Cell Carcinoma Progressed After Sunitinib or Another Antiangiogenic Treatment
    Roberto Iacovelli, Antonella Palazzo, Patrizia Trenta, Silvia Mezi, Denise Pellegrino, Giuseppe Naso, Enrico Cortesi · 2013 · American Journal of Clinical Oncology
  26. Suppression of Akt-HIF-1α signaling axis by diacetyl atractylodiol inhibits hypoxia-induced angiogenesis
    Sik‐Won Choi, Kwang‐Sik Lee, Jin Hwan Lee, Hyeon Jung Kang, Mi‐Ja Lee, Hyun Young Kim, Kie‐In Park, Sun‐Lim Kim, Hye Kyoung Shin, Woo Duck Seo · 2016 · BMB Reports
  27. Combination of mTOR and MAPK Inhibitors—A Potential Way to Treat Renal Cell Carcinoma
    Ashutosh Chauhan, Deepak Kumar Semwal, Mishra Satyendra, Sandeep Kumar Goyal, Rajendra Marathe, Ruchi Badoni Semwal · 2016 · Medical Sciences
  28. The role of curcumin in disruption of HIF-1α accumulation to alleviate adipose fibrosis via AMPK-mediated mTOR pathway in high-fat diet fed mice
    Zhixia Qiu, Shuihong Zhang, Aiyun Li, Jiaojiao Yu, Ning Li, Fang Huang, Baolin Liu · 2017 · Journal of Functional Foods
  29. Histone demethylase KDM4D inhibition suppresses renal cancer progression and angiogenesis through JAG1 signaling
    Hao Yan, Liangsong Zhu, Jin Zhang, Zongming Lin · 2021 · Cell Death Discovery
  30. Emerging drugs for the treatment of metastatic renal cancer
    Wolfram E. Samlowski, Nicholas J. Vogelzang · 2007 · Expert Opinion on Emerging Drugs
  31. Modulation of hypoxia-inducible factors (HIF) from an integrative pharmacological perspective
    Francisco Javier Rodríguez-Jiménez, Victoria Moreno‐Manzano · 2011 · Cellular and Molecular Life Sciences
  32. Everolimus in Metastatic Renal Cell Carcinoma after Failure of Initial Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor (VEGFr-TKI) Therapy: Results of an Interim Analysis of a Non-Interventional Study
    Lothar Bergmann, Peter Jürgen Goebell, Ulrich Kube, Manfred Kindler, Edwin Herrmann, Jan Janßen, Joerg Schmitz, Steffen Weikert, Gabriel Steiner, Andreas Jakob et al. · 2013 · Oncology Research and Treatment
  33. Targeting the mTOR Pathway in Tumor Malignancy
    Hengmiao Cheng, Marlena Walls, Sangita M. Baxi, Min-Jean Yin · 2013 · Current Cancer Drug Targets
  34. Rapamycin and WYE-354 suppress human gallbladder cancer xenografts in mice
    Helga L. Weber, Pamela Leal, Stefan Stein, Hana Kunkel, Patricia García, Carolina Bizama, Jaime A. Espinoza, Ismael Riquelme, Bruno Nervi, Juan Carlos Araya et al. · 2015 · Oncotarget
  35. Recent Advances in the Medical Treatment of Recurrent or Metastatic Renal Cell Cancer
    Rekha Anjali Kumbla, Robert A. Figlin, Edwin M. Posadas · 2016 · Drugs
  36. VHL Synthetic Lethality Signatures Uncovered by Genotype-Specific CRISPR-Cas9 Screens
    Ning Sun, Sakina M. Petiwala, Charles Lu, Jessica E. Hutti, Min Hu, Mufeng Hu, Marc H. Domanus, Diya Mitra, Sadiya N. Addo, Christopher P. Miller et al. · 2019 · The CRISPR Journal
  37. Current Trends in the Molecular Classification of Renal Neoplasms
    Andrew N. Young, Viraj A. Master, Mahul B. Amin · 2006 · The Scientific World JOURNAL
  38. Pomegranate extract inhibits EMT in clear cell renal cell carcinoma in a NF-κB and JNK dependent manner
    Jiabin An, Yanchuan Guo, Ting Wang, Allan J. Pantuck, Matthew B. Rettig · 2015 · Asian journal of urology
  39. Anti‐angiogenic therapy in renal cell cancer
    Ramaprasad Srinivasan, Andrew J. Armstrong, William L. Dahut, Daniel J. George · 2007 · British Journal of Urology
  40. Targeting Vascular Endothelial Growth Factor in Renal Cell Carcinoma
    Nilay S. Patel, Asıf Muneer, Christopher Blick, Manit Arya, Adrian Llewellyn Harris · 2009 · Tumor Biology
  41. Signaling Inhibitors in Metastatic Renal Cell Carcinoma
    Bernard J. Escudier · 2008 · The Cancer Journal
  42. Metformin alleviates nickel-refining fumes-induced aerobic glycolysis via AMPK/GOLPH3 pathway in vitro and in vivo
    Tong Zhang, Yue Wang, Yangyang Chen, Ying Gao, Dan Zhang, Shuo Jin, Wen-Xue Yao, Lina Li, Shikuan Yang, Yonghui Wu · 2022 · Ecotoxicology and Environmental Safety
  43. Disposition of desipramine, a sensitive cytochrome P450 2D6 substrate, when coadministered with intravenous temsirolimus
    Joseph P Boni, Richat Abbas, Cathie A. Leister, Jaime Burns, Ronald A. Jordan, Matthew Hoffmann, William DeMaio, Bruce A. Hug · 2008 · Cancer Chemotherapy and Pharmacology
  44. Acute cholecystitis in a patient with metastatic renal cell carcinoma treated with everolimus
    Bülent Çetin, Uğur Çoşkun, Ramazan Yıldız, Süleyman Buyukberber, Meltem Baykara, Mustafa Beneklı · 2010 · Journal of Oncology Pharmacy Practice
  45. VHL inactivation without hypoxia is sufficient to achieve genome hypermethylation
    Artem V. Artemov, Nadezhda Zhigalova, Svetlana V. Zhenilo, Alexander M. Mazur, Egor Prokhortchouk · 2018 · Scientific Reports
  46. Predictive chromosomal clusters of synchronous and metachronous brain metastases in clear cell renal cell carcinoma
    Angelika Gutenberg, Martin Nischwitz, Bastian Gunawan, Christina Enders, Klaus Jung, Markus Bergmann, W. Feiden, Rupert Egensperger, Kathy Keyvani, D. Stolke et al. · 2014 · Cancer Genetics
  47. Treatment of Advanced Renal Cell Carcinoma
    Ramaprasad Srinivasan, William Marston Linehan · 2012 · Elsevier eBooks
  48. Factors Influencing Overall Survival for Patients With Metastatic Clear-Cell Renal-Cell Carcinoma in Daily Practice
    Antoine Thiery-Vuillemin, Tiphaine Cholley, Fabien Calcagno, Marion Hugues, Tristan Maurina, Samuel Limat, Thierry Nguyen Tan Hon, Hamadi Almotlak, Guillaume Mouillet, Virginie Nerich · 2017 · Clinical Genitourinary Cancer
  49. Dihydrotanshinone I inhibits the translational expression of hypoxia-inducible factor-1α
    Jing Li, Chunliu Mi, Juan Ma, Ke Si Wang, Jung Joon Lee, Xuejun Jin · 2015 · Chemico-Biological Interactions
  50. Carbonic anhydrase IX as a predictive biomarker of response to kidney cancer therapy
    Sabina Signoretti, Meredith M. Regan, Michael B. Atkins · 2008 · British Journal of Urology
  51. Evaluation of everolimus in renal cell cancer
    Robert John Amato, Mika Stepankiw · 2013 · Expert Opinion on Pharmacotherapy
  52. Antitumor Synergism and Enhanced Survival with a Tumor Vasculature–Targeted Enzyme Prodrug System, Rapamycin, and Cyclophosphamide
    John J. Krais, Needa A. Virani, Patrick McKernan, Quang De Nguyen, Kar‐Ming Fung, Vassilios I. Sikavitsas, Carla D. Kurkjian, Roger G. Harrison · 2017 · Molecular Cancer Therapeutics
  53. Everolimus Exposure and Early Metabolic Response as Predictors of Treatment Outcomes in Breast Cancer Patients Treated with Everolimus and Exemestane
    Annelieke E.C.A.B. Willemsen, Lioe‐Fee de Geus‐Oei, Maaike de Boer, Jolien Tol, Yvonne J. L. Kamm, Paul C. de Jong, Marianne A. Jonker, Allert H. Vos, Willem Grootjans, Johannes W. B. de Groot et al. · 2018 · Targeted Oncology
  54. Everolimus and zoledronic acid—a potential synergistic treatment for lung adenocarcinoma bone metastasis
    Yongfeng Yu, Zhengbo Song, Shunfang Yang, Xiaohua Yang, Jie Zhang, Shun Lü · 2014 · Acta Biochimica et Biophysica Sinica
  55. Molecular Biology of Kidney Cancer
    William G. Kaelin · 2015 · Springer eBooks
  56. Signal‐transduction inhibitors in renal cell carcinoma
    Nicholas J. Vogelzang, Cora Nanette Sternberg · 2007 · British Journal of Urology
  57. Identification of Core Genes Involved in the Metastasis of Clear Cell Renal Cell Carcinoma
    Rui Peng, Yahui Wang, Likai Mao, Fang Fang, Han Guan · 2020 · Cancer Management and Research
  58. Synergistic antitumour effects of rapamycin and oncolytic reovirus
    Charles Comins, Guy R. Simpson, William Rogers, Kate Relph, Kevin Joseph Harrington, Alan A. Melcher, Victoria Roulstone, Joan Kyula, Hardev Pandha · 2018 · Cancer Gene Therapy
  59. Tyrosine Kinase Inhibitors Reduce Glucose Uptake by Binding to an Exofacial Site on hGLUT‐1: Influence on 18F‐FDG PET Uptake
    Vijaya L. Damaraju, Maral Aminpour, Michelle Kuzma, Philip Winter, Jordane Preto, Jack A. Tuszyński, Alexander J.B. McEwan, Michael B. Sawyer · 2020 · Clinical and Translational Science
  60. Temsirolimus
    Christian Stock, Massimo Zaccagnini, Michael Schulze, Doğu Teber, Jens Jochen Rassweiler · 2009 · Recent results in cancer research/Recent Results in Cancer Research
  61. Growth Signaling Networks Orchestrate Cancer Metabolic Networks
    Brendan D. Manning, Christian C. Dibble · 2024 · Cold Spring Harbor Perspectives in Medicine
  62. Deciphering molecular pathways in urological cancers: A gateway to precision therapeutics
    Kiavash Hushmandi, Najma Farahani, Behzad Einollahi, Shokooh Salimimoghadam, Mina Alimohammadi, Liping Liang, Le Liu, Gautam Sethi · 2025 · Journal of Advanced Research
  63. Rapamycin induces the anti-apoptotic protein survivin in neuroblastoma.
    Ayman Samkari, Zachary Aaron Cooper, Michael P. Holloway, Jiebin Liu, Rachel A. Altura · 2012 · PubMed Central
  64. HepaCAM Regulates Warburg Effect of Renal Cell Carcinoma via HIF-1α/NF-κB Signaling Pathway
    Yanru Fan, Liping Ou, Jiaxin Fan, Li Luo, Xiaohou Wu, Chunli Luo, Yingying Gao, Lingfang Niu · 2018 · Urology
  65. Shared pathobiology identifies AMPK as a therapeutic target for obesity and autosomal dominant polycystic kidney disease
    Ioan-Andrei Iliuta, Xuewen Song, Lauren Pickel, Amirreza Haghighi, Ravi R. Retnakaran, James William Scholey, Hoon‐Ki Sung, Gregory R. Steinberg, York Pei · 2022 · Frontiers in Molecular Biosciences
  66. Sex and SUVmax: Sex-Dependent Prognostication in Early Non–Small Cell Lung Cancer
    Zoe Wainer, Marissa G. Daniels, Jason Callahan, David Binns, Rodney J. Hicks, Phillip N. Antippa, Prudence Anne Russell, Naveed Zeb Alam, Matthew Conron, Benjamin Solomon et al. · 2012 · Journal of Nuclear Medicine
  67. Chemistry and Pharmacology of Rapamycin and Its Derivatives
    Robert T. Abraham, James J. Gibbons, Edmund I. Graziani · 2010 · The Enzymes
  68. PTEN in the haematopoietic system and its therapeutic indications
    Alison Cheung, Tak W. Mak · 2006 · Trends in Molecular Medicine
  69. Optimizing recent advances in metastatic renal cell carcinoma
    Kevin Dale Courtney, Toni K. Choueiri · 2009 · Current Oncology Reports
  70. Synergistic roles of p53 and HIF1α in human renal cell carcinoma-cell apoptosis responding to the inhibition of mTOR and MDM2 signaling pathways
    Peiqian Yang, Qingjun Liu, Hongliang Shen, Jun Lin, Xiuhong Xu, Zhengguo Ji, Xiao Han, Donghao Shang · 2016 · Drug Design Development and Therapy
  71. Epidemiology of Renal Cell Carcinoma
    Priti H. Patel, Sandy Srinivas · 2011 · Springer eBooks
  72. Emerging tyrosine kinase inhibitors for the treatment of renal cancer
    Roberto Iacovelli, Laurence K. Albiges, Bernard J. Escudier · 2015 · Expert Opinion on Emerging Drugs
  73. Roles of the mammalian target of rapamycin (mTOR) signaling pathway in the repair of hyperoxia-induced acute lung injury
    Shaohua Wang, Longhui Li, Dong-Mei Zou, Xue-Mei Zheng, Jian Deng · 2019 · Advances in Clinical and Experimental Medicine
  74. Fighting Malignancy in Organ Transplant Recipients
    Edward Kenneth Geissler · 2009 · Transplantation Proceedings
  75. Combination of physical activity, nutrition, or other metabolic factors and vaccine response
    W. Hance Kenneth · 2007 · Frontiers in bioscience
  76. Clinical outcomes in patients with metastatic renal cell carcinoma receiving everolimus or temsirolimus after sunitinib.
    Roberto Iacovelli, Giacomo Cartenì, Michèle Milella, Rossana Berardi, Giuseppe Di Lorenzo, Elena Verzoni, Mimma Rizzo, Matteo Santoni, Giuseppe Procopio · 2014 · Canadian Urological Association Journal
  77. Nilotinib alleviated acetaminophen-induced acute hepatic injury in mice through inhibiting HIF-1alpha/VEGF-signaling pathway
    Gehad M Menisy, Sherine Zakaria, Ghada Mohamed Suddek · 2022 · International Immunopharmacology
  78. The Research Progress of Metformin Regulation of Metabolic Reprogramming in Malignant Tumors
    Qihai Sui, Huiqiang Yang, Zhengyang Hu, Xing Jin, Zhencong Chen, Wei Jiang, Fenghao Sun · 2024 · Pharmaceutical Research
  79. mTOR Signaling in Angiogenesis
    Henry Mead, Mirjana Zeremski, Markus Otto Guba · 2009 · Humana Press eBooks
  80. Turning promise into progress for antiangiogenic agents in epithelial ovarian cancer
    Arne R.M. van der Bilt, Elisabeth G.E. de Vries, Steven de Jong, Hetty Timmer‐Bosscha, Ate G.J. van der Zee, Anna K.L. Reyners · 2012 · Critical Reviews in Oncology/Hematology
  81. Hypoxia-inducible factor as a transcriptional factor regulating gene expression in cancer cells
    Ewelina Dondajewska, Wiktoria Maria Suchorska · 2011 · Współczesna Onkologia
  82. Clinical experience and critical evaluation of the role of sorafenib in renal cell carcinoma
    Giuseppe Lombardi, Zustovich, Nicoletto, Pastorelli, Dal Bianco, Zorzi, Vittorina Zagonel · 2011 · Research and Reports in Urology
  83. Angioside: The role of Angiogenesis and Hypoxia in Lung Neuroendocrine Tumours According to Primary Tumour Location in Left or Right Parenchyma
    Anna La Salvia, Raffaella Carletti, Monica Verrico, Tiziana Feola, Giulia Puliani, Massimiliano Bassi, Franz Federico Sesti, Angelina Pernazza, Rossella Mazzilli, Giuseppe Lamberti et al. · 2022 · Journal of Clinical Medicine
  84. The Regulation and Interactions of the Hypoxia Inducible Factor Pathway in Carcinogenesis and Potential Cancer Therapeutic Strategies
    Niraj Konchady Shenoy, Makardhwaj Sarvadaman Shrivastava, Vineeth Sukrithan, Dimitra Papaspyridi, Karine Darbinyan · 2015 · Journal of Cancer Therapy
  85. Targeting PI3K by Natural Products: A Potential Therapeutic Strategy for Attention-deficit Hyperactivity Disorder
    Tayebeh Noori, Mousa Sahebgharani, Antoni Sureda, Eduardo Sobarzo-Sanchez, Sajad Fakhri, Samira Shirooie · 2022 · Current Neuropharmacology
  86. Research Translation and Personalized Medicine
    James Brugarolas · 2012 · Springer eBooks
  87. Use of mTOR inhibitors in the treatment of malignancies
    Nisha Anjali Mohindra, Francis Joseph Giles, Leonidas C. Platanias · 2014 · Expert Opinion on Pharmacotherapy
  88. Exploring the Role of Hypoxia and HIF-1α in the Intersection of Type 2 Diabetes Mellitus and Endometrial Cancer
    Alagappan V. S. Geetha, Kannan Harithpriya, Kumar Ganesan, Kunka Mohanram Ramkumar · 2025 · Current Oncology
  89. The convergence of tumor suppressors on the type I interferon pathway in clear cell renal cell carcinoma and its therapeutic implications
    Lauren E. Langbein, Rayan El Hajjar, William Y. Kim, Haifeng Yang · 2022 · American Journal of Physiology-Cell Physiology
  90. The Role of Insulin Receptor Substrate Proteins in Bronchopulmonary Dysplasia and Asthma: New Potential Perspectives
    Gökhan Görgişen, Malik Aydin, Olivier Mboma, Mira Y. Gökyildirim, Cho‐Ming Chao · 2022 · International Journal of Molecular Sciences
  91. Mechanism of action of everolimus in renal cell carcinoma
    Bernard J. Escudier, John A. Thompson · 2009 · Medical Oncology
  92. Everolimus for the treatment of pancreatic neuroendocrine tumors
    Georg Feldmann, Savita Bisht, Ute Schütte, Jens Haarmann, Peter Brossart · 2012 · Expert Opinion on Pharmacotherapy
  93. Bowel perforation associated with temsirolimus use in a recently irradiated patient
    Claire M. Mach, Anze Urh, Matthew Linley Anderson · 2014 · American Journal of Health-System Pharmacy
  94. Research of targeted therapy for renal cancer from 2006 to 2022: a bibliometric and visualized analysis
    Yuanqing Gou, Yongxin Fu, Yadong Li, Chuan Liu · 2023 · Translational Andrology and Urology
  95. Rational Therapy for Renal Cell Carcinoma Based on its Genetic Targets
    Jamie Christopher Messer, Joseph J. Drabick, Matthew G. Kaag · 2012 · Advances in experimental medicine and biology
  96. Axitinib Induced Recurrent Pneumothorax following Near-Complete Response of Renal Cell Carcinoma Lung Metastasis: An Unexpected Complication
    Francisco Andres Socola, Arturo Loaiza‐Bonilla, Pasquale W. Benedetto · 2012 · Case Reports in Oncological Medicine
  97. Cancer stem cells and addicted cancer cells
    Meike E. W. Logtenberg, Johannes Boonstra · 2013 · Oncology Discovery
  98. Malignant Epithelioid Angiomyolipoma: Tumor and Metabolic Response to Everolimus as Evaluated With Positron Emission Tomography
    Eliney Ferreira Faria, Francesco Turturro, Priya Rao, Surena F. Matin · 2013 · Clinical Genitourinary Cancer
  99. Clinical experience with everolimus in the second-line treatment of advanced renal cell carcinoma
    Daniele Alesini, Claudia Mosillo, Giuseppe Naso, Enrico Cortesi, Roberto Iacovelli · 2015 · Therapeutic Advances in Urology
  100. Self-assembled ratiometric sensor for specific detection of hypoxia in living cells based on lanthanide-doped upconversion nanoparticles and gold nanoparticles
    Xuetao Zhang, Wenhao Shu, Manxiao Cheng, Linna Wang, Xiang Ran · 2023 · Nanotechnology